Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

Little is known about what causes ovarian cancer, and there is no way to detect it early yet. About 75% of the time when ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

See why the ovary − often reduced to its reproductive role − menopause, age and estrogen affect a woman’s health throughout ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...